<DOC>
	<DOCNO>NCT00079885</DOCNO>
	<brief_summary>To compare efficacy safety tigecycline levofloxacin treatment subject CAP require hospitalization . The co-primary efficacy endpoint study clinical response clinically evaluable population clinical response clinical modify intent-to-treat population TOC visit . The primary efficacy analysis first determine whether tigecycline noninferior levofloxacin . If tigecycline find noninferior , analyse determine whether tigecycline statistically well levofloxacin .</brief_summary>
	<brief_title>Study Evaluating Tigecycline v Levofloxacin Hospitalized With Community-Acquired Pneumonia</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Bacterial</mesh_term>
	<mesh_term>Cross Infection</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Tigecycline</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>Male female subject ≥ 18 year ag . Subjects hospitalized CAP IV antibiotic treatment indicate The presence fever ( within 24 hour prior randomization ) , define oral temperature &gt; 38°C/100.4°F , axillary temperature &gt; 38.1°C/100.6°F , tympanic temperature &gt; 38.5°C/ 101.2°F , rectal/core temperature &gt; 39°C/102.2°F OR hypothermia ( within 24 hour prior randomization ) , core temperature &lt; 35°C/95° Any concomitant condition , opinion investigator , would preclude evaluation response make unlikely contemplated course therapy could complete ( eg , life expectancy &lt; 30 day ) Hospitalization within 14 day prior onset symptom Residence longterm care facility nursing home ≥14 day onset symptom</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Bacterial Pneumonia</keyword>
</DOC>